Submitted by mphilemon@resea... on Thu, 02/04/2010 - 18:25
Cardiac Safety Results of a Docetaxel/Cyclophosphamide/Trastuzumab Combination in Patients with HER2-Positive Early-Stage Breast Cancer
Slides from a presentation at SABCS 2009 and transcribed comments from a recent interview with Mark D Pegram, MD (12/23/09)
Dr Pegram is Full Professor of Medicine and Director for the Translational Research Program at the Braman Family Breast Cancer Research Institute at UM Sylvester Comprehensive Cancer Center in Miami, Florida.
Presentation discussed in this issue:
Jones SE et al. Cardiac safety results of a Phase II trial of adjuvant docetaxel, cyclophosphamide plus trastuzumab in Her2+ early stage breast cancer patients. San Antonio Breast Cancer Symposium 2009;Abstract 5082.
Go to previous Journal Club Go to next Journal Club